People living with HIV have a significantly increased risk of cardiovascular disease that requires a different level of ...

In 2021, approval of cabotegravir (Apretude) as the first long-acting PrEP option provided patients an option to move from ...

The Food and Drug Administration is currently reviewing a first-of-its-kind, twice-yearly injectable medication that experts say could revolutionize HIV prevention. The drug, Lenacapavir, has shown ...